{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nIn chronic myeloid leukemia, hsa‐miR‑2278 has been identified as a key tumor suppressor that counteracts imatinib resistance by targeting vital oncogenic pathways. Upregulation of miR‑2278 in imatinib‐resistant CML cells led to a marked decrease in cell proliferation and a significant increase in apoptosis. Mechanistically, the miRNA exerts its therapeutic effects by directly downregulating the expression of critical mRNAs, including AKT2, STAM2, and STAT5A, at both transcriptional and translational levels. This targeted suppression interferes with the signaling cascades that normally promote survival and proliferation, thereby restoring sensitivity to imatinib and offering a promising strategy to overcome chemotherapeutic resistance in CML therapy."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Burçin Tezcanlı Kaymaz, Nur Selvi Günel, Metin Ceyhan, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted \"hsa-miR-2278\" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Tumour Biol (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s13277-015-3509-9"}], "href": "https://doi.org/10.1007/s13277-015-3509-9"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25953263"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25953263"}]}]}]}